Pharmacological subgroup
R07A – ANDERE MITTEL FÜR DEN RESPIRATIONSTRAKT
48Decisions
52Patient groups
Added benefit by patient group
- Major5
- Considerable5
- Minor1
- Non-quantifiable17
- Not proven24
Subgroups
- R07AX Andere Mittel für den Respirationstrakt 48 decisions
Decisions, newest first
- 2025-10-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2025-10-16KaftrioIvacaftor/Tezacaftor/ElexacaftorMajor: 1 of 3 patient groupsConsiderable: 1 of 3 patient groupsNon-quantifiable: 1 of 3 patient groups
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNon-quantifiable
- 2024-05-16KaftrioIvacaftor/Tezacaftor/ElexacaftorNon-quantifiable
- 2024-01-18OrkambiLumacaftor/IvacaftorNon-quantifiable
- 2022-08-04KalydecoIvacaftorNot proven
- 2022-08-04KalydecoIvacaftorNot proven
- 2022-08-04KalydecoIvacaftorNot proven
- 2022-08-04KalydecoIvacaftorNon-quantifiable
- 2022-08-04KalydecoIvacaftorConsiderable
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorNon-quantifiable
- 2022-08-04KaftrioIvacaftor/Tezacaftor/ElexacaftorConsiderable
- 2022-03-18OrkambiLumacaftor/IvacaftorNon-quantifiable
- 2021-11-19KalydecoIvacaftorNot proven
- 2021-11-19KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2021-11-19KalydecoIvacaftorNot proven
- 2021-11-19KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2021-11-19KalydecoIvacaftorNot proven
- 2021-11-19KaftrioIvacaftor/Tezacaftor/ElexacaftorNot proven
- 2021-05-20KalydecoIvacaftorNot proven
- 2021-05-20KalydecoIvacaftorNot proven
- 2021-05-20KalydecoIvacaftorNon-quantifiable
- 2021-05-20SymkeviTezacaftor/IvacaftorNot proven
- 2021-05-20SymkeviTezacaftor/IvacaftorNot proven
- 2021-05-20KalydecoIvacaftorNon-quantifiable
- 2021-02-18KalydecoIvacaftorMajor
- 2021-02-18KalydecoIvacaftorMajor
- 2021-02-18KaftrioIvacaftor/Tezacaftor/ElexacaftorMajor
- 2021-02-18KaftrioIvacaftor/Tezacaftor/ElexacaftorMajor
- 2020-12-17KalydecoIvacaftorNon-quantifiable: 2 of 2 patient groups
- 2020-12-17SymkeviTezacaftor/IvacaftorNot proven
- 2020-12-17SymkeviTezacaftor/IvacaftorNot proven
- 2020-06-04KalydecoIvacaftorNon-quantifiable
- 2020-02-20KalydecoIvacaftorMinor
- 2020-02-20KalydecoIvacaftorNon-quantifiable
- 2020-02-20KalydecoIvacaftorNot proven
- 2020-02-20KalydecoIvacaftorNot proven
- 2020-02-20KalydecoIvacaftorNon-quantifiable
- 2020-02-20KalydecoIvacaftorNon-quantifiable
- 2020-02-20KalydecoIvacaftorConsiderable: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2018-08-02OrkambiLumacaftor/IvacaftorNon-quantifiable
- 2016-06-02OrkambiLumacaftor/IvacaftorConsiderable
Data status: 2026-10-29